Tag Archives: Therapy

Reservoirs of HIV-infected cells that can’t be reached by antiretroviral therapy associated with an important marker of cardiovascular disease risk

The increased risk of cardiovascular disease observed in people with HIV taking effective antiretroviral therapy, even when they have an undetectable viral load, could be down to reservoirs of HIV-infected cells that cannot be reached by current treatments, according to research from San Francisco published in JAMA Network Open. Researchers found that higher levels of… Read More »

Writing as Therapy for Generalized Anxiety Disorder

I’ve been writing on Medium for a little over a month. I don’t aspire to be a fancy-schmancy writer who rakes in a few thousand dollars a month. I’m not good enough and I prefer the security of my day job with its healthcare and bi-weekly paycheck. Not having read much on Medium before, I’m… Read More »

Triple therapy helps control severe asthma

Asthma affects approximately 20 million adults in the US. It is a common cause of workplace and school absenteeism, and is one of the leading causes of hospitalizations in the US. Between 5% and 10% of asthmatics have frequent, persistent symptoms despite treatment with multiple medications, and are categorized as “difficult to treat” and “severe”… Read More »

FDA Approves Kesimpta (ofatumumab) Targeted B-cell Therapy for Patients with Relapsing Multiple Sclerosis

FDA Approves Kesimpta (ofatumumab) Targeted B-cell Therapy for Patients with Relapsing Multiple Sclerosis Print this page Basel, August 20, 2020 — Novartis today announced that the US Food and Drug Administration (FDA) has approved Kesimpta® (ofatumumab, formerly OMB157) as an injection for subcutaneous use for the treatment of relapsing forms of multiple sclerosis (RMS), to include clinically… Read More »

FDA Approves Viltepso (viltolarsen) for the Treatment of Duchenne Muscular Dystrophy in Patients Amenable to Exon 53 Skipping Therapy

FDA Approves Viltepso (viltolarsen) for the Treatment of Duchenne Muscular Dystrophy in Patients Amenable to Exon 53 Skipping Therapy Print this page PARAMUS, N.J., Aug. 12, 2020 /PRNewswire/ — NS Pharma, Inc. announced today that the U.S. Food & Drug Administration (FDA) has approved Viltepso (viltolarsen) injection for patients with Duchenne muscular dystrophy (DMD) who… Read More »